N1,n12-diacetylspermine as tumor marker

Abstract

A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.

1 . A tumor marker comprising N 1 ,N 12 -diacetylspermine.  
   
   
       2 . A method of detecting a tumor, comprising reacting an antibody to N 1 ,N 12 -diacetylspermine with a biological sample.  
   
   
       3 . A method of evaluating the state of a tumor, comprising reacting an antibody to N 1 ,N 12 -diacetylspermine with a biological sample to thereby detect N 1 ,N  12 -diacetylspermine, and evaluating the state of the tumor using the resultant detection results as an indicator.  
   
   
       4 . The method according to  claim 2 , wherein the biological sample is urine.  
   
   
       5 . The method according to  claim 2 , wherein the tumor is at least one selected from the group consisting of urogenital malignant tumors, colorectal cancer, breast cancer, pancreatic cancer, biliary tract cancer, lung cancer, liver cancer, uterine cervix cancer, brain tumor, myelogenous leukemia and malignant lymphoma.  
   
   
       6 . The method according to  claim 3 , wherein the state of the tumor is at least one selected from the group consisting of the presence/absence of cancer, the degree of progression of cancer, the degree of malignancy of cancer, the presence/absence of metastasis of cancer and the presence/absence of recurrence of cancer.  
   
   
       7 . The method according to  claim 6 , wherein the cancer is early cancer.  
   
   
       8 . An antibody to DiAcSpm, which has at least one property selected from the following (a) and (b): 
 (a) cross-reactivity with N 1 -AcSpd: 0.1% or less    (b) total cross-reactivity with DiAcSpm analogues present in urine: 5% or less.    
   
   
       9 . The antibody according to  claim 8 , which is a polyclonal antibody or monoclonal antibody.  
   
   
       10 . A tumor detection kit comprising an antibody to N 1 ,N 12 -diacetylspermine.  
   
   
       11 . The kit according to  claim 10 , wherein the antibody has at least one property selected from the following (a) and (b): 
 (a) cross-reactivity with N 1 -AcSpd: 0. 1% or less    (b) total interference on the measurement results caused by its cross-reaction with DiAcSpm analogues present in urine: 5% or less.    
   
   
       12 . The kit according to  claim 10 , wherein the antibody is a polyclonal antibody or monoclonal antibody.  
   
   
       13 . The kit according to  claim 10 , wherein the tumor is selected from the group consisting of urinary tract malignant tumors, large bowel cancer, breast cancer, pancreatic cancer, biliary tract cancer, lung cancer, liver cancer, uterine cervix cancer, brain tumor, myelogenous leukemia and malignant lymphoma.  
   
   
       14 . The kit according to  claim 10 , which has at least one property selected from the following (a) to (c): 
 (a) lower detection limit in actual measurement: 9.06 nM    (b) within-run reproducibility: CV=10% or less    (c) between-day reproducibility: CV=10% or less.    
   
   
       15 . The method according to  claim 3 , wherein the biological sample is urine.  
   
   
       16 . The method according to  claim 3 , wherein the tumor is at least one selected from the group consisting of urogenital malignant tumors, colorectal cancer, breast cancer, pancreatic cancer, biliary tract cancer, lung cancer, liver cancer, uterine cervix cancer, brain tumor, myelogenous leukemia and malignant lymphoma.